(bren-TUK-sih-mab veh-DOH-tin)
This page contains brief information about brentuximab vedotin and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Brentuximab vedotin is approved to treat:
- Anaplastic large cell lymphoma. Brentuximab vedotin is used in:
- Adults whose cancer is systemic and has not gotten better after treatment with combination chemotherapy.
- Adults whose cancer has not been treated. Brentuximab vedotin is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone.
- Cutaneous anaplastic large cell lymphoma that is primary. Brentuximab vedotin is used in adults who have received other systemic therapy.
- Classic Hodgkin lymphoma. Brentuximab vedotin is used:
- After an autologous stem cell transplant (ASCT) in adults who have a high risk that the cancer will come back or get worse.
- In adults whose cancer has not gotten better after an ASCT. Brentuximab vedotin is also used in adults whose cancer has not gotten better after at least two treatments with combination chemotherapy and who cannot receive an ASCT.
- With doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine in adults with stage III or stage IV Hodgkin lymphoma whose cancer has not been treated.
- With doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone, and cyclophosphamide in children aged 2 years and older whose cancer has not been treated and who have a high risk that the cancer will come back or get worse.
- Mycosis fungoides (a type of cutaneous T-cell lymphoma). Brentuximab vedotin is used in adults whose cancer has the CD30 protein and who have received other systemic therapy.
- Peripheral T-cell lymphoma that has the CD30 protein. Brentuximab vedotin is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone in adults.
Brentuximab vedotin is also being studied in the treatment of other conditions and types of cancer.
More About Brentuximab Vedotin
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Brentuximab Vedotin – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Brentuximab Vedotin – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
